Calzada announces organisational revamp
Calzada (ASX:CZD) is on the hunt for a managing director for its corporate and PolyNovo units, as well as new clinical and regulatory talent, as part of an organisational restructuring.
The company announced it is seeking a candidate with broad experience commercialising medical devices or pharmaceuticals to take on the managing director role.
Calzada director David McQuillan and chartered accountant Philip Powell will take the role of joint acting managing directors until a permanent replacement is found.
The company’s board also plans to brief recruitment agents to identify experienced candidates to help the company expand its clinical, regulatory, commercial, quality and manufacturing expertise.
As part of the restructuring, current PolyNovo CEO Laurent Fossaert will leave the company once a transition to the new organisational structure is complete.
Calzada chairman David Williams commented that with the job hunt, the company is “creating some exciting new roles of outstanding Australians, including a number we expect will be returning from overseas”.
PolyNovo last month commenced a clinical trial of its NovoSorb BTM dermal scaffold product in burns. The company has also been trialling the product in applications including free-flap donor site repair surgery.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
